Stocks
BioXcel Financial Statements (BTAI) |
||||||||||
| BioXcelsmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 12.03.2021 | 11.03.2022 | 16.03.2023 | 01.05.2023 | 22.03.2024 | 14.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.375 | 0.375 | 1.38 | 2.28 | |||
| Operating Income, bln rub | -82.3 | -106.9 | -159.6 | -159.6 | -171.8 | -75.0 | ||||
| EBITDA, bln rub | ? | -82.0 | -107.0 | -157.5 | -157.4 | -165.4 | -56.2 | |||
| Net profit, bln rub | ? | -82.0 | -106.6 | -171.8 | -171.8 | -179.1 | -71.0 | |||
| OCF, bln rub | ? | -66.4 | -82.2 | -135.3 | -135.3 | -155.0 | -84.1 | |||
| CAPEX, bln rub | ? | 0.316 | 0.445 | 0.139 | 0.139 | 0.020 | 0.000 | |||
| FCF, bln rub | ? | -66.7 | -82.6 | -135.5 | -135.5 | -155.0 | -84.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 82.3 | 106.9 | 160.0 | 160.0 | 171.9 | 75.0 | ||||
| Cost of production, bln rub | 0.188 | 0.297 | 0.020 | 0.020 | 1.26 | 2.18 | ||||
| R&D, bln rub | 58.0 | 52.7 | 91.2 | 91.2 | 84.3 | 34.0 | ||||
| Interest expenses, bln rub | 0.027 | 0.040 | 8.21 | 8.21 | 13.3 | 14.5 | ||||
| Assets, bln rub | 219.9 | 239.4 | 205.9 | 205.9 | 73.7 | 48.9 | ||||
| Net Assets, bln rub | ? | 206.7 | 221.7 | 76.8 | 76.8 | -56.5 | -85.6 | |||
| Debt, bln rub | 1.64 | 1.40 | 94.2 | 94.2 | 101.4 | 104.6 | ||||
| Cash, bln rub | 213.1 | 233.0 | 193.7 | 193.7 | 65.2 | 40.4 | ||||
| Net debt, bln rub | -211.5 | -231.6 | -99.6 | -99.6 | 36.2 | 64.2 | ||||
| Ordinary share price, rub | 46.2 | 20.3 | 21.5 | 21.5 | 2.95 | 4.00 | ||||
| Number of ordinary shares, mln | 21.7 | 26.4 | 28.0 | 28.0 | 29.1 | 42.4 | ||||
| Market cap, bln rub | 1 002 | 536 | 602 | 602 | 86 | 170 | ||||
| EV, bln rub | ? | 790 | 305 | 502 | 502 | 122 | 234 | |||
| Book value, bln rub | 207 | 222 | 77 | 77 | -57 | -86 | ||||
| EPS, rub | ? | -3.78 | -4.04 | -6.13 | -6.13 | -6.15 | -1.67 | |||
| FCF/share, rub | -3.07 | -3.13 | -4.84 | -4.84 | -5.32 | -1.98 | ||||
| BV/share, rub | 9.53 | 8.41 | 2.74 | 2.74 | -1.94 | -2.02 | ||||
| EBITDA margin, % | ? | -42 012% | -41 969% | -11 987% | -2 467% | |||||
| Net margin, % | ? | -45 826% | -45 826% | -12 975% | -3 119% | |||||
| FCF yield, % | ? | -6.65% | -15.4% | -22.5% | -22.5% | -180.4% | -49.6% | |||
| ROE, % | ? | -39.7% | -48.1% | -223.8% | -223.8% | 316.9% | 82.9% | |||
| ROA, % | ? | -37.3% | -44.5% | -83.5% | -83.5% | -242.9% | -145.2% | |||
| P/E | ? | -12.2 | -5.03 | -3.50 | -3.50 | -0.48 | -2.39 | |||
| P/FCF | -15.0 | -6.49 | -4.44 | -4.44 | -0.55 | -2.02 | ||||
| P/S | ? | 1 605 | 1 605 | 62.3 | 74.5 | |||||
| P/BV | ? | 4.85 | 2.42 | 7.84 | 7.84 | -1.52 | -1.98 | |||
| EV/EBITDA | ? | -9.64 | -2.85 | -3.19 | -3.19 | -0.74 | -4.16 | |||
| Debt/EBITDA | 2.58 | 2.16 | 0.63 | 0.63 | -0.22 | -1.14 | ||||
| R&D/CAPEX, % | 18 353% | 11 844% | 65 640% | 65 640% | 421 630% | |||||
| CAPEX/Revenue, % | 37.1% | 37.1% | 1.45% | 0 | ||||||
| BioXcel shareholders | ||||||||||
